In conclusion, the outstanding efficacy of CDK4/6 inhibitors in the treatment of advanced HR+/HER2- BC highlights the need to develop molecular biomarkers that may be able to predict efficacy and/or resistance and provide a prognostic stratification of patients. Here, ERBB2 is linked to breast cancer.